Roche Holding AG Total Liabilities
Roche Holding AG total liabilities. Based on the latest financial reports, Roche Holding AG (ROG) has total liabilities worth CHF62.82 Billion CHF (≈ $79.43 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Roche Holding AG liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Roche Holding AG (1998–2025)
Total liabilities of Roche Holding AG from 1998 to 2025. This chart illustrates how Roche Holding AG's total liabilities have evolved over time, based on quarterly financial data. Explore Roche Holding AG long-term investment allocation to see how much of total assets are deployed in long-term investments.
Roche Holding AG Competitors by Total Liabilities
The table below lists competitors of Roche Holding AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kweichow Moutai Co Ltd
SHG:600519
|
China | CN¥39.03 Billion |
|
Palo Alto Networks Inc
NASDAQ:PANW
|
USA | $20.97 Billion |
|
Netflix Inc
NASDAQ:NFLX
|
USA | $28.98 Billion |
|
Goldman Sachs Group Inc
NYSE:GS
|
USA | $2.00 Trillion |
|
Toyota Motor Corporation ADR
NYSE:TM
|
USA | $62.39 Trillion |
|
AstraZeneca PLC
F:ZEGA
|
Germany | €68.48 Billion |
|
Wells Fargo & Company
NYSE:WFC
|
USA | $2.03 Trillion |
|
Roche Holding AG
SW:ROP
|
Switzerland | CHF62.82 Billion |
Liability Composition Analysis (1998–2025)
This chart breaks down Roche Holding AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ROG total asset value.
Liquidity & Leverage Metrics
Roche Holding AG Total Liabilities Ratios Explained
Roche Holding AG total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.20 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Roche Holding AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Roche Holding AG (1998–2025)
The table below shows the annual total liabilities of Roche Holding AG from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CHF62.82 Billion ≈ $79.43 Billion |
-4.29% |
| 2024-12-31 | CHF65.64 Billion ≈ $82.99 Billion |
+14.75% |
| 2023-12-31 | CHF57.20 Billion ≈ $72.32 Billion |
+1.90% |
| 2022-12-31 | CHF56.14 Billion ≈ $70.97 Billion |
-12.25% |
| 2021-12-31 | CHF63.97 Billion ≈ $80.88 Billion |
+37.97% |
| 2020-12-31 | CHF46.37 Billion ≈ $58.62 Billion |
-1.82% |
| 2019-12-31 | CHF47.22 Billion ≈ $59.70 Billion |
-1.93% |
| 2018-12-31 | CHF48.15 Billion ≈ $60.88 Billion |
+1.01% |
| 2017-12-31 | CHF47.67 Billion ≈ $60.27 Billion |
-5.45% |
| 2016-12-31 | CHF50.42 Billion ≈ $63.74 Billion |
-3.90% |
| 2015-12-31 | CHF52.46 Billion ≈ $66.33 Billion |
-2.81% |
| 2014-12-31 | CHF53.98 Billion ≈ $68.25 Billion |
+31.90% |
| 2013-12-31 | CHF40.93 Billion ≈ $51.74 Billion |
-14.87% |
| 2012-12-31 | CHF48.08 Billion ≈ $60.78 Billion |
+2.09% |
| 2011-12-31 | CHF47.09 Billion ≈ $59.54 Billion |
-4.59% |
| 2010-12-31 | CHF49.36 Billion ≈ $62.40 Billion |
-24.24% |
| 2009-12-31 | CHF65.15 Billion ≈ $82.37 Billion |
+192.59% |
| 2008-12-31 | CHF22.27 Billion ≈ $28.15 Billion |
-10.49% |
| 2007-12-31 | CHF24.88 Billion ≈ $31.45 Billion |
-9.87% |
| 2006-12-31 | CHF27.60 Billion ≈ $34.89 Billion |
-0.08% |
| 2005-12-31 | CHF27.62 Billion ≈ $34.92 Billion |
+11.46% |
| 2004-12-31 | CHF24.78 Billion ≈ $31.33 Billion |
-18.27% |
| 2003-12-31 | CHF30.32 Billion ≈ $38.34 Billion |
-20.67% |
| 2002-12-31 | CHF38.22 Billion ≈ $48.32 Billion |
-7.72% |
| 2001-12-31 | CHF41.42 Billion ≈ $52.36 Billion |
+10.45% |
| 2000-12-31 | CHF37.50 Billion ≈ $47.41 Billion |
-7.25% |
| 1999-12-31 | CHF40.43 Billion ≈ $51.11 Billion |
+22.28% |
| 1998-12-31 | CHF33.06 Billion ≈ $41.80 Billion |
-- |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and tr… Read more